Mitera Biosciences is an early-stage biotechnology company in Bellevue, Washington developing immunosuppressive therapeutics for autoimmune disease and organ transplant rejection. Its approach is built on a natural human protein produced by the placenta during pregnancy and expressed in the thymus, with intellectual property exclusively licensed from Cedars-Sinai Medical Center. The mechanism targets three arms of the immune response: impairing effector T cells, expanding regulatory T cells, and downregulating B cell function. The company emerged from stealth with $1.75 million in funding and is led by co-founder, president and CEO Kevin Chow, previously co-founder and CEO of Vitaeris, which was acquired by CSL Behring.